Gene Therapy and Optogenetic Goggles for Retinitis Pigmentosa. Interview with Dr. Bernard Gilly, CEO of GenSight Biologics

GenSight Biologics, a biopharmaceutical company based in France, is developing gene therapies for rare diseases that cause blindness. The company has recently received approval in the UK for its Phase I/II PIONEER trial, which will test a treatment c...

Source: Medgadget - February 9, 2018 Category: Medical Devices Authors: Conn Hastings Tags: Exclusive Genetics Ophthalmology Source Type: blogs